CI
VRTX icon

Corient IA’s Vertex Pharmaceuticals VRTX Stock Holding History

Corient IA’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Hold
440
– – 0.2% 159
2026
Q1 		$196K Sell
440
-60
-12% -$28K 0.18% 203
2025
Q4 		$227K Buy
+500
New +$216K 0.21% 188
2025
Q3 		– Sell
-600
Closed -$267K – 284
2025
Q2 		$267K Sell
600
-100
-14% -$46.1K 0.16% 240
2025
Q1 		$339K Buy
+700
New +$326K 0.24% 175

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Corient IA's VRTX Position: Q2 2026 in Review

Corient IA held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 440 shares worth $219K. The position accounts for 0.2% of the portfolio, ranked #159.

Corient IA first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $339K in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Corient IA held 440 shares of Vertex Pharmaceuticals worth $219K as of Q2 2026.
  • Corient IA left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.2% of Corient IA's portfolio in Q2 2026, its #159 holding.
  • Corient IA first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Corient IA's Vertex Pharmaceuticals position peaked at $339K in Q1 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Corient IA's 13F filing for Q2 2026, filed 12 Aug 2026.